Living Cell Technologies Ltd (LCT) is an advanced biotechnology company currently listed on the Australian Stock Exchange. LCT’s focus is on market-driven encapsulated living cell products, for the treatment of Huntington's disease, haemophilia and insulin-dependent diabetes. LCT’s business was formed in 1987 to research cell extraction and to develop procedures for advanced living-cell replacement therapies.
Living Cell Technologies Limited
ASX:LCT ISIN:AU000000LCT6
新闻
2010年12月31日澳洲股市报告包括:Moly Mines (ASX:MOL)(TSE:MOL)首批54,500吨铁矿石已发往中国;Living Cell Technologies Limited (ASX:LCT)宣布筹资5,750,000澳元;OM Holdings Limited (ASX:OMH)拿到兴建马来西亚烧结和熔炼厂所需地块;Perilya Limited (ASX:PEM)提高Broken Hill项目矿产资源量和矿石储量。
澳洲股市前一天触及六周高点后,周三开盘下挫,回吐出先前涨幅。S&P/ASX200指数早盘下挫0.3%,报4558.1点, 综合指数下跌0.28%, 报4573.8点。金融股和工业股下跌0.5%,材料股下挫0.4%。
###
104,875 公司背景浏览
- 本页浏览人次: (过去7日: 24) (过去30日: 94) (自发布以来: 13533)